docetaxel + icotinib

Docetaxel + icotinib is a combination therapy consisting of docetaxel, a cytotoxic chemotherapy agent, and icotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This combination has shown promising results in the treatment of non-small cell lung cancer (NSCLC), particularly in advanced stages. The combination works through multiple mechanisms, with docetaxel providing cytotoxic effects while icotinib inhibits EGFR signaling pathways. Studies have shown that this combination can effectively reduce serum tumor markers and improve quality of life in NSCLC patients while causing fewer adverse reactions compared to other combination therapies.